OLALA: A Study of Long-Term Responders on Olaparib
Who can take part
Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.
You may be able to take part in this clinical trial if you:
- you have epithelial ovarian, primary peritoneal or fallopian tube cancer and
- you have been taking olaparib for at least 2 years and your cancer has either not returned or has remained stable during this time or
- you previously took olaparib for at least 2 years
This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.
About the trial
Researchers in this study are trying to find out more about the mechanisms of action of a drug called olaparib. olaparib is a PARP inhibitor which is a targeted treatment for ovarian cancer. Researchers wish to find out why some women's ovarian cancer responds well to olaparib while other ovarian cancers don't. This information will help them to better identify patients who might benefit from this therapy.
This type of research is known as an observational study. Researchers will observe women who are/were already taking olaparib as part of their normal clinical care or as part of another clinical trial.
If you take part in this study, you'll need to:
- allow researchers access to your medical history and results of investigations for your ovarian cancer.
- complete a questionnaire.
- donate tissue samples from any previous biopsies or surgery that you have had for your ovarian cancer.
- donate blood samples for research purposes.
- have an additional tumour biopsy if your cancer progresses while on olaparib (optional).
- allow researchers to contact you by telephone to follow your progress.
